Comparison of PD‐L1 detection assays and corresponding significance in evaluation of diffuse large B‐cell lymphoma. (31st May 2019)

• Record Type: Journal Article
• Authors: Huang, Sixia; Nong, Lin; Liang, Li; Zheng, Yalin; Wang, Wei; Liu, Jumei; Li, Dong; Li, Xin; Wang, Ying; Zhang, Bo; Li, Ting
• Is Part Of: Cancer medicine. Volume 8:Number 8(2019:Jul.)
• Page Start: 3831
• Page End: 3845
• Publication Date: 2019-05-31
• Subjects: DLBCL -- FISH -- IHC -- PMBCL -- RNAscope; 616.994005
• DOI: 10.1002/cam4.2316
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: The expression of programmed cell death ligand 1 (PD‐L1) is a biomarker for immunotherapy, but approved detection method is absent in diffuse large B‐cell lymphoma (DLBCL). Here, we performed three methods including immunohistochemistry (IHC) (clone SP263 and SP142), RNAscope, and fluorescence in situ hybridization (FISH) to evaluate PD‐L1 status on a cohort of DLBCL including 94 of DLBCL‐NOS, 25 of primary mediastinal large B‐cell lymphoma (PMBCL) and 7 of double‐hit lymphoma (DHL). SP263 with 25% for immune cell (IC) or combined cell and SP142 with 10% for tumor cell (TC), 20% for both of IC and combined cell were proved to have corresponding survival prognostic. Combined + showed comparable prognostic value with TC + and IC + . SP263 and SP142 showed strong concordance ( k = 0.788) with combined + rates of 33.3% (42/126) and 34.9% (44/126), respectively. In DLBCL‐NOS, TC + by SP263 preferred to non‐GCB and immunoblastic variant DLBCL‐NOS ( P = 0.029 and P = 0.004). Combined + (SP263 and SP142) were associated with more than one extranodal site involved ( P = 0.006, P = 0.042), higher ECOG PS scores ( P = 0.001, P < 0.001), high IPI risk ( P = 0.012, P = 0.005), and poor treatment response ( P = 0.095, P = 0.002). IC + by SP263 and SP142 were both independent risk factors ( P = 0.027, P = 0.037). 9p24.1 locus amplification and gain were identified in 4.3% and 7.6% DLBCL‐NOS and indicated shorter overall survival ( P = 0.004). Positive rate of PD‐L1 by RNAscope was 36.5%, while no clinical significance shown. PD‐L1 positive rates were all higher in PMBCL and DHL than in DLBCL‐NOS by SP263, SP142, RNAscope, and FISH ( P = 0.001, P < 0.001, P = 0.005 and P < 0.001, respectively). In conclusion, combined PD‐L1 expression by IHC was potentially reliable and convenient as a predicting biomarker. SP263 staining was easier to evaluate and recognized more PD‐L1‐stained cells, but SP142 presented a better prognostic indicator. FISH and RNAscope could be used as supplementary assays. PMBCL itself was a sensitive cohort for immunotherapy. Abstract : Combined PD‐L1 expression by IHC was potentially reliable and convenient as a predicting biomarker. SP263 was easier to evaluate and more sensitive, but SP142 presented a better prognostic indicator. FISH and RNAscope could be used as supplementary assays. PMBCL itself was a sensitive cohort for immunotherapy.